Letermovir Prophylaxis for Cytomegalovirus Reactivation in β Thalassemia Major Children after Hematopoietic Cell Transplantation
- Resource Type
- Article
- Authors
- Shi, Lingling; Liu, Rongrong; Zhang, Zhongming; Huang, Cuifeng; Liu, Lianjin; Yao, Yibin; Wei, Zhenbin; Wei, Shuyi; Gan, Zhaoping; Sun, Na; Liu, Beicai; Huang, Rui; Zhou, Xuemei; Chen, Yinghua; Liu, Qifa; Lai, Yongrong
- Source
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p7053-7053, 1p
- Subject
- Language
- ISSN
- 00064971; 15280020
Background:Cytomegalovirus(CMV) is one of the most important infections following allogeneic haematopoietic stem cell transplantation (HSCT). Although Letermovir is licensed for prophylaxis of CMV infection in allogeneic hematopoietic cell transplant adult CMV seropositive patients. There are limited data for letermovir as primary CMV prophylaxis in pediatric patients . The objective of the study was to analyze the the use of letermovir for prophylaxis from CMV infection in β thalassemia major children undergoing allo-HSCT in a single center.